VGI Health Technology (XNEC:VTL) Days Payable : 0.00 (As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Days Payable?

VGI Health Technology's average Accounts Payable for the six months ended in . 20 was A$0.00 Mil. VGI Health Technology's Cost of Goods Sold for the six months ended in . 20 was A$0.00 Mil.

The historical rank and industry rank for VGI Health Technology's Days Payable or its related term are showing as below:

XNEC:VTL's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 149.7
* Ranked among companies with meaningful Days Payable only.

VGI Health Technology's Days Payable stayed the same from . 20 (0.00) to . 20 (0.00).

VGI Health Technology Days Payable Historical Data

The historical data trend for VGI Health Technology's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Days Payable Chart

VGI Health Technology Annual Data

Trend

Days Payable

VGI Health Technology Semi-Annual Data

Days Payable

Competitive Comparison of VGI Health Technology's Days Payable

For the Biotechnology subindustry, VGI Health Technology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Days Payable distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Days Payable falls into.

VGI Health Technology Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

VGI Health Technology's Days Payable for the fiscal year that ended in . 20 is calculated as

	Days Payable (A: . 20 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: . 20 )	+	Accounts Payable (A: . 20 ))	/	count )	/	Cost of Goods Sold (A: . 20 )	*	Days in Period
=	( (	+	)	/	1 )	/		*	365
=	0					/		*	365
=	N/A

VGI Health Technology's Days Payable for the quarter that ended in . 20 is calculated as:

	Days Payable (Q: . 20 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: . 20 )	+	Accounts Payable (Q: . 20 ))	/	count )	/	Cost of Goods Sold (Q: . 20 )	*	Days in Period
=	( (	+	)	/	1 )	/		*	365 / 2
=	0					/		*	365 / 2
=	N/A

VGI Health Technology Days Payable Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines